Can we identify patients with risk factors that would predict cardiotoxicity?
• A: The incidence and severity of left ventricular cardiac dysfunction was highest in patients who received Herceptin concurrently with anthracycline-containing chemotherapy regimens. An analysis of potential risk factors for Herceptin/chemotherapy-induced CHF was conducted in adjuvant study NSABP B-31 (Tan-Chiu et al, 2005). Factors that statistically affected the risk of CHF were: • Declining LVEF after completion of AC chemotherapy • Increasing age *These treatment modification guidelines stated in the Herceptin Full Prescribing Information should not be used as a substitute for independent medical management. The safety of continuation or resumption of Herceptin in patients with Herceptin-induced left ventricular cardiac dysfunction has not been studied.
